Amoéba has received marketing authorization in France for its biofungicide AXPERAChassieu, July 01, 2026 (GLOBE NEWSWIRE) -- Amoéba (FR0011051598 - ALMIB), industrial greentech specialized in the development of natural microbiological solutions, announces that it has obtained marketing authorization for its biofungicide AXPERA in France. This first authorisation, granted by ANSES following the evaluation conducted by France in its capacity as rapporteur Member State for European Union, now allows the other concerned Member States concerned to proceed with and finalise their national authorisation procedures in the coming weeks and months, according to each country’s specific timelines.
A natural breakthrough in protecting cereals and field cropsSyngenta and Amoeba SA to develop and commercialize biocontrol solutions for EU and UK
